DrugPatentWatch Database Preview
Taro Company Profile
» See Plans and Pricing
What is the competitive landscape for TARO, and what generic alternatives to TARO drugs are available?
TARO has two hundred and thirty-eight approved drugs.
There are eight US patents protecting TARO drugs. There are four tentative approvals on TARO drugs.
There are thirty-two patent family members on TARO drugs in twelve countries and one hundred and forty supplementary protection certificates in fourteen countries.
Summary for Taro
International Patents: | 32 |
US Patents: | 8 |
Tradenames: | 125 |
Ingredients: | 108 |
NDAs: | 238 |
Patent Litigation for Taro: | See patent lawsuits for Taro |
PTAB Cases with Taro as petitioner: | See PTAB cases with Taro as petitioner |
Drugs and US Patents for Taro
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Taro Pharm Inds | HYDROCORTISONE BUTYRATE | hydrocortisone butyrate | CREAM;TOPICAL | 076654-001 | Aug 3, 2005 | AB1 | RX | No | No | Start Trial | Start Trial | ||||
Taro | LAMOTRIGINE | lamotrigine | TABLET, CHEWABLE;ORAL | 079204-001 | Feb 4, 2009 | AB | RX | No | No | Start Trial | Start Trial | ||||
Taro | CITALOPRAM HYDROBROMIDE | citalopram hydrobromide | TABLET;ORAL | 077278-003 | Mar 22, 2006 | DISCN | No | No | Start Trial | Start Trial | |||||
Taro | ENALAPRIL MALEATE | enalapril maleate | TABLET;ORAL | 075657-003 | Jan 23, 2001 | AB | RX | No | No | Start Trial | Start Trial | ||||
Taro | A/T/S | erythromycin | SOLUTION;TOPICAL | 062405-001 | Nov 18, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
Taro | ONDANSETRON HYDROCHLORIDE | ondansetron hydrochloride | SOLUTION;ORAL | 077009-001 | Nov 30, 2007 | AA | RX | No | No | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Taro
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Taro Pharms | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | 6,528,086 | Start Trial |
Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-002 | Jan 17, 2008 | 6,071,523 | Start Trial |
Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-001 | Jan 17, 2008 | 5,881,926 | Start Trial |
Taro Pharms | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | 5,919,479 | Start Trial |
Taro Pharms | TOPICORT | desoximetasone | SPRAY;TOPICAL | 204141-001 | Apr 11, 2013 | 5,990,100 | Start Trial |
Taro | FLO-PRED | prednisolone acetate | SUSPENSION;ORAL | 022067-002 | Jan 17, 2008 | 6,656,482 | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TARO drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Topical Lotion | 0.5% | ➤ Subscribe | 2011-03-16 |
➤ Subscribe | Topical Spray | 0.25% | ➤ Subscribe | 2013-12-18 |
International Patents for Taro Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2612578 | Start Trial |
Australia | 2011205730 | Start Trial |
China | 101247786 | Start Trial |
New Zealand | 566117 | Start Trial |
South Korea | 20080044245 | Start Trial |
Australia | 2006278620 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Taro Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1856135 | 2090014-8 | Sweden | Start Trial | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE OR SOLVATE OF FOSTAMATINIB OR THE PH ARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
1948158 | 93075 | Luxembourg | Start Trial | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN, C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3'-METHYL-2-(PENTANYOL(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE) DE TRISODIUM HEMIPENTAHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
1620113 | CA 2015 00045 | Denmark | Start Trial | PRODUCT NAME: IVERMECTIN, 22, 23-DIHYDROAVERMECTINB1A + 22,23-DIHRODROAVERMECTIN B1B FOR USE IN THE TREATMNET OF RESACEA; NAT. REG. NO/DATE: 54123 20150422; FIRST REG. NO/DATE: MT MA 117/01101 20150402 |
2203431 | CR 2015 00014 | Denmark | Start Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119 |
2203431 | 92666 | Luxembourg | Start Trial | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
1586316 | 122011100019 | Germany | Start Trial | PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.